Drugs in Dev. Neurology
Phase I
Taiwan 
A Study of Topical XG004 in Participants With Osteoarthritis of the Knee
Details : XG004 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 12, 2022
Details : Proceeds will be used to advance phase 1 trials of two pipeline candidates, EI-1071 and EI-001 and take three immuno-oncology assets towards IND applications .
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 23, 2021
Details : Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 26, 2020
Pharmacokinetics Study of XG005 Capsule
Details : XG005 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : Pregabalin,Naproxen
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NDA Application of XG005 will Follows a Regulatory Pathway Bosed on FDA’s Feedback
Details : XG005 is a drug conjugate of naproxen and pregabalin which is being investigated for the management of acute pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 22, 2020
Lead Product(s) : Pregabalin,Naproxen
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 XG005-03 Topical Study
Details : XG005-03 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 25, 2020
Phase 1 Pharmacokinetics, Safety, and Tolerability Study
Details : XG005 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2019
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy Volunteers
Details : Nalbuphine HCl is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 18, 2015
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
